Policy statement--postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia

Area of Science:

• Neonatal Medicine
• Pediatric Pulmonology
• Pharmacology

Background:

• Bronchopulmonary dysplasia (BPD) is a significant cause of morbidity in preterm infants.
• Postnatal glucocorticoids have been used to manage BPD, but optimal dosing and risks remain debated.
• Current evidence requires re-evaluation to guide clinical practice.

Purpose of the Study:

• To review current information on postnatal glucocorticoid use for BPD in preterm infants.
• To provide updated recommendations on the efficacy and safety of these treatments.
• To guide clinicians in balancing treatment benefits against potential adverse effects.

Main Methods:

• Systematic review of existing literature on postnatal glucocorticoid therapy for BPD.
• Analysis of data regarding different glucocorticoid doses and preparations.
• Evaluation of therapeutic benefits versus adverse effects.

Main Results:

• High-dose dexamethasone (0.5 mg/kg/day) offers no additional benefit over lower doses and is not recommended.
• Insufficient evidence exists to recommend specific doses or preparations of other glucocorticoids.
• Clinical judgment is essential for managing BPD with glucocorticoids.

Conclusions:

• Avoid high-dose dexamethasone for BPD treatment in preterm neonates.
• Further research is needed to establish evidence-based recommendations for other glucocorticoid regimens.
• Individualized patient assessment is crucial when considering glucocorticoid therapy for BPD.